Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01514981 · ClinicalTrials.gov registry record · Phase 1

AMG 761 in Adults With Asthma

A Phase 1 study, sponsored by Amgen.

Terminated
Registry status
Phase 1
Development phase
7
Enrollment target

NCT01514981 is a Phase 1 study that was terminated before completion, run by Amgen. The registered enrollment target is 7 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01514981, a Phase 1 study, was terminated before completion, sponsored by Amgen.

TERMINATED
Registry status
Phase 1
Development phase
7 participants
Enrollment target

Study Summary

The purpose of this study is to determine that no significant safety issues will be identified following a single dose of AMG 761 in asthma subjects that would preclude further development of AMG 761.

Interventions

  • DRUG Placebo
  • DRUG AMG 761

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2011-12
Est. Completion 2014-02
Phase Phase 1

Sponsor

Amgen

558 total trials

What the Registry Record Tells You About NCT01514981

The ClinicalTrials.gov registry entry for NCT01514981 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01514981 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01514981 about?

NCT01514981 is a clinical study titled "AMG 761 in Adults With Asthma". The purpose of this study is to determine that no significant safety issues will be identified following a single dose of AMG 761 in asthma subjects that would preclude further development of AMG 761.

What is the current status of trial NCT01514981?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2011-12. Estimated completion is 2014-02.

What interventions are being tested in trial NCT01514981?

The interventions under investigation include: Placebo (DRUG), AMG 761 (DRUG).

Who is sponsoring clinical trial NCT01514981?

This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.